Company news

Gain Therapeutics, Inc. news in 2026

Gain Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences

November 5, 2026

Gain Therapeutics to Attend the 2026 Maxim Growth Summit

October 8, 2026

Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration

October 1, 2026

Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders

September 29, 2026

Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference

September 17, 2026

Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference

August 25, 2026

Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update

August 11, 2026

Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update

July 16, 2026

Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease

June 29, 2026

Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

June 10, 2026

Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026

May 25, 2026

Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update

May 11, 2026

Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026

April 23, 2026

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update

March 25, 2026

Gain Therapeutics to Present at the 38th Annual ROTH Conference

March 19, 2026

Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026

March 18, 2026

Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update

March 11, 2026

Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 19, 2026

Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week

January 7, 2026

Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287

January 6, 2026

Decks in 2026